A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAÏVE MANTLE CELL LYMPHOMA (BRUIN MCL-321)
- Registry ID
- LOXO-BTK-20019 (J2N-OX-JZNM)
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- LOXO ONCOLOGY INC
- Start date
- 2021-11-19
- Last update
- 2021-03-19
Conditions
Related clinical trials
- A PHASE II STUDY OF SONROTOCLAX PLUS ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PLANNED FOR STANDARD OF CARE CAR-T CELL THERAPY
- A MULTICENTRE, PHASE II, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY OF ACALABRUTINIB IN COMBINATION WITH VENETOCLAX AND RITUXIMAB IN PARTICIPANTS WITH TREATMENT NAÏVE MANTLE CELL LYMPHOMA (TRAVERSE).
- A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING GLOFITAMAB
AS A SINGLE AGENT VERSUS INVESTIGATOR¿S CHOICE IN PATIENTS WITH
RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
- A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING ZANUBRUTINIB (BGB-3111) PLUS RITUXIMAB VERSUS BENDAMUSTINE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA(MCL) WHO ARE INELIGIBLE FOR STEM CELL TRANSPLANTATION
- A PHASE II STUDY OF ACALABRUTINIB IN COMBINATION WITH R-CHOP CHEMOTHERAPY IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF BENDAMUSTINE AND RITUXIMAB (BR) ALONE VERSUS IN COMBINATION WITH ACALABRUTINIB (ACP-196) IN SUBJECTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA
View on source registry